Adagene (ADAG) Total Non-Current Liabilities (2019 - 2025)
Adagene's (ADAG) quarterly Total Non-Current Liabilities came in at -$205.1 billion in Q4 2025, down 529515.03% year-on-year from N/an in Q4 2024, and down 529515.03% on a QoQ basis from $38.7 million in Q4 2024.
Adagene (ADAG) Total Non-Current Liabilities (2019 - 2025) Analysis & Trends
Adagene (ADAG) has 7 years of Total Non-Current Liabilities data on file, last reported at -$205.1 billion in Q4 2025.
- On a quarterly basis, Total Non-Current Liabilities fell 529515.03% year-over-year to -$205.1 billion in Q4 2025; TTM through Dec 2025 was -$205.1 billion, a 529515.03% decrease from a year earlier, with the FY2025 full-year figure at -$205.1 billion, down 529515.03% from the prior year.
- Total Non-Current Liabilities for Q4 2025 stood at -$205.1 billion, down from $38.7 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for ADAG reached as high as $45.2 million in Q4 2023 and fell as low as -$205.1 billion in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged -$36.4 billion across 5 years, with a median of -$13.8 billion in 2021.
- Across the five-year window, Total Non-Current Liabilities surged 100.16% in 2023 and plunged 529515.03% in 2025, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $32.9 million in 2021, then slumped by 87289.64% to -$28.6 billion in 2022, then jumped by 100.16% to $45.2 million in 2023, then decreased by 14.22% to $38.7 million in 2024, then plunged by 529515.03% to -$205.1 billion in 2025.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were -$205.1 billion in Q4 2025, $38.7 million in Q4 2024, and $45.2 million in Q4 2023.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | 110.28 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 1.98 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 949,738.67 |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 40.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 746.94 Mn |
| 10 | Adagene | 198.85 Mn | 198.85 Mn | - | -205.12 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -205.12 Bn |
| Dec 31, 2024 | 38.74 Mn |
| Dec 31, 2023 | 45.17 Mn |
| Jun 30, 2023 | -27.68 Bn |
| Dec 31, 2022 | -28.65 Bn |
| Jun 30, 2022 | -29.80 Bn |
| Dec 31, 2021 | 32.86 Mn |
| Jun 30, 2021 | 31.58 Mn |
| Dec 31, 2020 | 19.11 Mn |
| Dec 31, 2019 | 8.70 Mn |